KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Total Non-Current Liabilities (2016 - 2025)

Teva Pharmaceutical Industries' Total Non-Current Liabilities history spans 17 years, with the latest figure at $19.4 billion for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities fell 6.87% year-over-year to $19.4 billion, compared with a TTM value of $19.4 billion through Dec 2025, down 6.87%, and an annual FY2025 reading of $19.4 billion, down 6.87% over the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $19.4 billion at Teva Pharmaceutical Industries, down from $21.1 billion in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $25.9 billion in Q1 2021, with the low at $19.4 billion in Q4 2025.
  • Average Total Non-Current Liabilities over 5 years is $23.1 billion, with a median of $23.3 billion recorded in 2022.
  • Year-over-year, Total Non-Current Liabilities grew 0.44% in 2023 and then dropped 12.66% in 2024.
  • Tracing TEVA's Total Non-Current Liabilities over 5 years: stood at $25.4 billion in 2021, then dropped by 5.71% to $23.9 billion in 2022, then dropped by 3.5% to $23.1 billion in 2023, then decreased by 9.94% to $20.8 billion in 2024, then fell by 6.87% to $19.4 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Total Non-Current Liabilities are $19.4 billion (Q4 2025), $21.1 billion (Q3 2025), and $21.4 billion (Q2 2025).